Evidence map›Paper›PMID 34173097›Full record

ReviewBulletin of experimental biology and medicine2021

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease.

V Kh Khavinson, N S Lin'kova, R S Umnov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

V Kh KhavinsonDepartment of Biogerontology, St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, Russia.
N S Lin'kovaDepartment of Biogerontology, St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, Russia. miayy@yandex.ru.
R S UmnovDepartment of Biogerontology, St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroprotective peptides are promising candidate molecules for the treatment of Alzheimer's disease (AD). Oral application of KED (Lys-Glu-Asp) improved memory and attention in elderly individuals with functional CNS disorders. Peptide KED also restores synaptic plasticity in in vitro model of AD. This review is focused on the analysis of the influence of KED peptide on the expression of genes and synthesis of proteins regulating apoptosis, aging, neurogenesis, and involved in AD pathogenesis. Analysis of published reports and our experimental findings suggests that KED regulates the expression of genes of cell aging and apoptosis (р16, р21), genes (NES, GAP43) and proteins (nestin, GAP43) of the neuronal differentiation, and genes involved in AD pathogenesis (SUMO, APOE, and IGF1). The study the effectiveness of neuroprotective peptide KED in animal models of AD seems to be very important.

Indexed as

Alzheimer DiseaseNeurogenesisAgedAgingAnimalsCellular SenescenceDisease Models, AnimalHumansNeuronal PlasticityOligopeptidesSignal Transductionlysyl-glutamyl-aspartic acidOligopeptidesAlzheimer’s diseasegene expressionneuroprotectionpeptide KED

Identifiers

PMID34173097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.